Produção Nacional
Revisado por pares
Adverse events of metronidazole and amoxicillin: Retrospective analysis of a large data set of five randomized clinical trials
2022; Wiley; Volume: 49; Issue: 11 Linguagem: Inglês
10.1111/jcpe.13704
ISSN1600-051X
AutoresBelén Retamal‐Valdes, Ana Paula Laranjeira Tavares, Sarah Monique, Hélio Doyle Pereira da Silva, Maria Josefa Mestnik, Poliana Mendes Duarte, Tamires Szeremeske Miranda, Ivan Borges, Geisla Mary Silva Soares, Marcelo Faveri, Nídia Cristina Castro dos Santos, Yasmin Teixeira das Graças, Maria Luisa Silveira Souto, Marcela Giudicissi, Giuseppe Alexandre Romito, Luciana Saraiva, Cláudio Mendes Pannuti, Luciene Cristina Figueiredo, Magda Feres,
Tópico(s)Antimicrobial Resistance in Staphylococcus
ResumoTo evaluate the frequency of side effects associated with intake of metronidazole (MTZ) + amoxicillin (AMX) in periodontal treatment, and to explore associations between these events and patients' features.Data of five randomized clinical trials testing MTZ + AMX adjunctive to mechanical therapy were evaluated. Volunteers answered an adverse event questionnaire.Information from 656 subjects was assessed. The frequency of side effects in the antibiotic- and placebo-treated groups ranged from 1.0% to 17.7% and 0.9% to 13.7%, respectively. The events more frequently observed in the antibiotic than in the placebo group were diarrhoea and metallic taste (p < .05). Diabetes significantly raised the odds of a patient reporting discomfort (odds ratio [OR] = 2.6), diarrhoea (OR = 4.0), weakness (OR = 6.0) and excessive sleepiness (OR = 2.9). In systemically healthy volunteers, using antibiotics 3 months post-mechanical treatment (healing phase) (OR = 3.0), being a woman (OR = 3.9) and aged ≤49 (OR = 4.5) significantly increased the chances of reporting adverse events.The occurrence of side effects during MTZ + AMX treatment ranged from uncommon (1%) to very common (17.7%). The main factors raising the chances of a patient reporting adverse events were diabetes and taking antibiotics in the healing phase, instead of in the active phase of treatment. Patients ≤ 49 years old and females also tend to report more side effects.
Referência(s)